Literature DB >> 12724631

Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study.

Jeffrey A Norton1, H Richard Alexander, Douglas L Fraker, David J Venzon, Fathia Gibril, Robert T Jensen.   

Abstract

OBJECTIVE: To analyze the results of a prospective study of 176 patients with Zollinger-Ellison syndrome (ZES) (138 sporadic, 38 MEN1) undergoing 207 operations over a 17-year period. SUMMARY BACKGROUND DATA: The existence of lymph node (LN) primary gastrinoma causing ZES is controversial.
METHODS: Three groups of patients were compared: LN only resected, cured, and no relapse (likely LN primary); same criteria but relapse (unlikely LN primary); and duodenal primary and LN metastases (Duo-LN).
RESULTS: Forty-five (26%) had only LN(s) as the initial tumor found. Twenty-six of the 45 (58%) fit the definition of a likely LN primary because they were apparently cured postresection. At 10.4 +/- 1.2 years, 69% of the 26 patients with likely LN primary tumors have remained cured and have LN primaries. In the 8 of 26 with recurrent ZES, it occurred at 5 +/- 1 years, and 3 had duodenal gastrinoma that had been missed. Ten percent (13/138) of all patients with sporadic ZES and 0% (0/38) with ZES and MEN1 remained cured with only a LN tumor removed. In patients with sporadic gastrinomas no clinical, laboratory, or radiographic localization feature differed among patients with likely LN primary (n = 16) and those with unlikely LN primary (n = 6) or those with Duo-LN (n = 37). In the likely LN primary group, the largest LN was 2.2 +/- 0.2 cm, the number of LNs removed was 1.3 +/- 0.1 (25% > or =1 LN), and 78% were in the gastrinoma triangle, which also did not differ from the other 2 groups. Disease-free survival was similar in the likely LN primary group, patients with Duo-LN, and those with pancreatic primaries.
CONCLUSIONS: These results support the conclusion that primary LN gastrinomas occur and are not rare (approximately 10% of sporadic cases). These results suggest that a proportion (25%) of these tumors are either multiple or malignant. Because no clinical, laboratory, or tumoral characteristic distinguishes patients with LN primary tumors, all patients with ZES undergoing surgery should have an extensive exploration to exclude duodenal or pancreatic tumors and routine removal of lymph nodes in the gastrinoma triangle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12724631      PMCID: PMC1514510          DOI: 10.1097/01.SLA.0000064375.51939.48

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  40 in total

1.  Primary nodal gastrinomas.

Authors:  M E Herrmann; M C Ciesla; G Chejfec; S A DeJong; S L Yong
Journal:  Arch Pathol Lab Med       Date:  2000-06       Impact factor: 5.534

2.  The origin of sporadic gastrinomas within the gastrinoma triangle: a theory.

Authors:  E Passaro; T J Howard; M P Sawicki; P C Watt; B E Stabile
Journal:  Arch Surg       Date:  1998-01

3.  Zollinger-Ellison syndrome. Clinical presentation in 261 patients.

Authors:  P K Roy; D J Venzon; H Shojamanesh; A Abou-Saif; P Peghini; J L Doppman; F Gibril; R T Jensen
Journal:  Medicine (Baltimore)       Date:  2000-11       Impact factor: 1.889

4.  Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management.

Authors:  B Termanini; F Gibril; J C Reynolds; J L Doppman; C C Chen; C A Stewart; V E Sutliff; R T Jensen
Journal:  Gastroenterology       Date:  1997-02       Impact factor: 22.682

5.  Surgery to cure the Zollinger-Ellison syndrome.

Authors:  J A Norton; D L Fraker; H R Alexander; D J Venzon; J L Doppman; J Serrano; S U Goebel; P L Peghini; P K Roy; F Gibril; R T Jensen
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

6.  Is reoperation for gastrinoma excision indicated in Zollinger-Ellison syndrome?

Authors:  N T Jaskowiak; D L Fraker; H R Alexander; J A Norton; J L Doppman; R T Jensen
Journal:  Surgery       Date:  1996-12       Impact factor: 3.982

7.  Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.

Authors:  H R Alexander; D L Fraker; J A Norton; D L Bartlett; L Tio; S B Benjamin; J L Doppman; S U Goebel; J Serrano; F Gibril; R T Jensen
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

8.  Surgical treatment of localized gastrinoma within the liver: a prospective study.

Authors:  J A Norton; G M Doherty; D L Fraker; H R Alexander; J L Doppman; D J Venzon; F Gibril; R T Jensen
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

9.  Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1.

Authors:  M P MacFarlane; D L Fraker; H R Alexander; J A Norton; I Lubensky; R T Jensen
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

10.  An immunohistochemical survey for neuroendocrine cells in regional pancreatic lymph nodes: a plausible explanation for primary nodal gastrinomas? Mayo Clinic Pancreatic Surgery Group.

Authors:  N D Perrier; K P Batts; G B Thompson; C S Grant; T B Plummer
Journal:  Surgery       Date:  1995-12       Impact factor: 3.982

View more
  39 in total

1.  [A young man with chronic diarrhea and epigastric pain].

Authors:  Juliane Buchkremer; Hans-Jörg Epple; Hanno Tröger; Frank Heller; Bernd Frericks; Esther Herpel; Christa Flechtenmacher; Markus Wolfgang Büchler; Martin Zeitz
Journal:  Med Klin (Munich)       Date:  2010-04

2.  Primary hepatic gastrinoma: an unusual case of zollinger-ellison syndrome.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

3.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

Review 4.  Surgery for primary pancreatic neuroendocrine tumors.

Authors:  Jeffrey A Norton
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

5.  Surgery increases survival in patients with gastrinoma.

Authors:  Jeffrey A Norton; Douglas L Fraker; H R Alexander; Fathia Gibril; David J Liewehr; David J Venzon; Robert T Jensen
Journal:  Ann Surg       Date:  2006-09       Impact factor: 12.969

6.  [Rare occurrence of fulminant acid burn of the esophagus].

Authors:  C Knebel; R Bumm; K Becker; M Burian; J R Siewert
Journal:  Chirurg       Date:  2008-08       Impact factor: 0.955

7.  Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.

Authors:  Scott H Long; Marc J Berna; Michelle Thill; Andrea Pace; Tapas K Pradhan; K Martin Hoffmann; Jose Serrano; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

8.  Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome?

Authors:  Jeffrey A Norton; H Richard Alexander; Douglas L Fraker; David J Venzon; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

Review 9.  Surgical treatment of sporadic gastrinoma.

Authors:  Kerstin Lorenz; Henning Dralle
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 10.  Gastric acid hypersecretory states: recent insights and advances.

Authors:  Nauramy Osefo; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.